Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2025 08:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.
February 05, 2025 08:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.
December 10, 2024 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
December 09, 2024 08:00 ET | Source: Myriad Genetics, Inc.

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment

Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.